LOS ANGELES, Sept. 22, 2015 /PRNewswire/
-- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE
MKT: IMUC) today announced that its Board of Directors has
appointed Mark A. Schlossberg and
Gregg A. Lapointe as Board
members.
Mr. Schlossberg and Mr. Lapointe are seasoned business
executives. Mr. Schlossberg has more than 15 years of experience in
the biotechnology, pharmaceutical and medical device industries,
and broad expertise in general management, legal affairs, finance,
business development, and mergers and acquisitions. Mr.
Lapointe has deep and broad executive, financial, operational,
commercial and general management experience in large and small
biopharmaceutical companies. Mr. Schlossberg has been appointed to
the Audit and Nominating & Governance Committees of the Board,
and Mr. Lapointe has been appointed to the Compensation Committee
of the Board.
Andrew Gengos, ImmunoCellular
Chief Executive Officer, commented: "Mark is an accomplished
executive with a proven track record both in general management and
legal support of key functions including, intellectual property,
manufacturing, regulatory, finance, mergers and acquisitions,
licensing, and commercial operations. Gregg is an accomplished,
hands-on executive with extensive management and board experience
in both large and small companies with differing areas of
therapeutic focus and business models. Their diverse industry
backgrounds will be valuable as we execute our product development
strategies based on both our dendritic cell and stem cell
technology platforms and pursue business development transactions
to further build ImmunoCellular into a leading cancer immunotherapy
company."
Mr. Schlossberg currently serves as Senior Vice President,
General Counsel and Corporate Secretary of Impax Laboratories,
Inc., where he is part of the senior management team responsible
for the strategic direction and financial condition of the company.
He leads the legal team and previously had responsibility for the
healthcare compliance team. Prior to Impax, he served as Vice
President, Associate General Counsel of Amgen Inc., where he led
the legal department, and was responsible for corporate governance,
securities law, licensing, mergers and acquisitions, global
operations, and sales and marketing compliance. Prior to joining
Amgen, he held legal and business positions at Medtronic, Inc., and
legal positions at Diageo plc, RJR Nabisco, Inc. and Mudge Rose Guthrie Alexander & Ferdon. Mr.
Schlossberg holds a Bachelor of Sciences in business
administration, finance from the University of
Southern California and a Juris Doctor degree from
Emory University.
Mr. Lapointe is currently the Chief Executive Officer of Cerium
Pharmaceuticals, Inc., a specialty pharmaceutical company. He
previously served as Chief Operating Officer and then as Chief
Executive Officer of Sigma-Tau Pharmaceuticals, Inc., a
pharmaceutical company focused on rare disorders and the U.S.
wholly-owned subsidiary of Sigma-Tau Finanziaria S.p.A. Lapointe is
a Certified Public Accountant (Illinois). He holds a Bachelor of Commerce
degree from Concordia University of
Montreal, a Graduate Diploma in Public Accountancy from
McGill University of Montreal and a
Master of Business Administration degree from Duke University. Mr. Lapointe also serves on the
Boards of Directors of SciClone Pharmaceuticals, Inc., Soligenix,
Inc., and Raptor Pharmaceuticals Corp.
The appointment of Mr. Schlossberg and Mr. Lapointe as
independent members of the Company's Board of Directors enables
ImmunoCellular to regain compliance with the listing standards of
the New York Stock Exchange MKT regarding the majority of
independent directors' requirement as well as having at least three
independent directors serving on the Audit Committee.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that
is developing immune-based therapies for the treatment of brain and
other cancers. ImmunoCellular has concluded a phase 2 trial of its
lead product candidate, ICT-107, a dendritic cell-based
immunotherapy targeting multiple tumor-associated antigens on
glioblastoma stem cells. ImmunoCellular's pipeline also includes:
ICT-121, a dendritic cell immunotherapy targeting the CD133 antigen
on stem cells in recurrent glioblastoma; ICT-140, a dendritic cell
immunotherapy targeting antigens on ovarian cancer stem cells; and
the Stem-to-T-cell research program which engineers the patient's
hematopoietic stem cells to generate antigen-specific
cancer-killing T-cells. To learn more about ImmunoCellular, please
visit www.imuc.com.
Forward-Looking Statements for ImmunoCellular Therapeutics
This press release contains certain forward-looking statements that
are subject to a number of risks and uncertainties, including the
risk that ICT-107 can be further successfully developed or
commercialized. Additional risks and uncertainties are described in
IMUC's most recently filed quarterly report on Form 10-Q and
annual report on Form 10-K. Except as required by law, IMUC
undertakes no obligation to update any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contact:
ImmunoCellular Therapeutics, Ltd.
Investor Relations
Jane Green
415.348.0010 direct
415.652.4819 mobile
jane@jmgcomm.com
Logo -
http://photos.prnewswire.com/prnh/20140109/AQ43875LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/immunocellular-therapeutics-appoints-mark-a-schlossberg-and-gregg-a-lapointe-to-its-board-of-directors-300146603.html
SOURCE ImmunoCellular Therapeutics, Ltd.